ImetelChat

MF - Myelofibrosis Market Size Myelofibrosis market will exceed $1 billion by 2025 https://www.chemdiv.com/myelofibrosis-market-will-exceed-1-billion-2025-says-globaldata/ Myelofibrosis treatment market will reach USD $971.5 Million By 2024 https://www.globenewswire.com/news-release/2018/07/24/15409...

AML - Acute Myeloid Leukemia Market Size Global Acute Myeloid Leukemia Market $2.2 Billion by 2025 https://www.ihealthcareanalyst.com/global-acute-myeloid-leukemia-treatment-market/ Since there is a progression into AML for about 1/3 of MDS patients, it makes sense to discuss this indication next. G...

Go Big or Go Home – Pt.3 – Imetelstat’s Potential Market Size - MDS The previous 2 posts in this series – well actually 3 – Pt. 2 was split in half, laid out the evidence of a much larger patient population globally for MDS then is now being reported. As a fairly newly recognized Hematologic Disease...

Thanks Andrew. I'll try and draft up something in the next few days. Hopefully others here take up the cause as well. The patients who desperately need Imet as frontline should be in our thoughts first and foremost. There are many here with a stronger understanding of the science than myself and cou...

(cont.)......... 4. Poverty / Economic Conditions – This (2015) abstract / article from Pakistan, which also mentions Iran, touches on insufficient treatment due to economic conditions; “a lack of expertise and a sky rocketing cost of transplant in the private sector. Eventually all the high and ver...

Go Big, or Go Home - Pt 2 In conjunction with Imetelstats future marketplace is emerging evidence of a booming and sometimes misrepresented patient population around the world. Countries such as China and India could easily have up to 5x or more then that of the US patient population when factoring ...

Go Big, or Go Home - Targeting just about every major hematologic myeloid malignancy is not only a confirmation of Imetelstats efficiency of doing exactly that, but it ratchets up the possibilities for Geron as a leader in a space which has yet to scratch the surface. The resonating tone from the 3 ...

Probably one of the most accurate and direct observations I've seen posted with regards to a delay in treatment with Imetelstat as far as the patients are concerned. Bravo Andrew for your sensible understanding of patient needs, while current options are driving them into poor prognosis. FDA and EMA...

Partner in the Wings? Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants 05/21/2020 "Stifel and MTS Health Partners are acting as joint book-running managers for the proposed offering." It's looking like the majority of MTS PARTNERS "Transactions" are mergers of some t...

Have to agree with Ryan that a partner would "take it through and be a part of the commercialization of the drug, not an arbitrage of stock shares." It's most likely the only scenario that makes sense for a potential partner. My take, and of course it's only that - I know as much as the next guy.......

Thank you, Andrew, for the kind words and ability to post here on your board. I do feel a sense of privilege for this opportunity. With that said I would like to address a few of my fellow longs who have questioned the reasoning for my “termination” from the YMB - in particular Cathy, Martin, Rocky,...

Great observations on the meetings and abstracts Andrew. As always a lot to digest. The TN patients that you, Ryan and Martin discussed a few weeks back became a real eye opener for me. If I'm not mistaken, approx 25% of the P2 patients fell under this category......I never realized how substantial ...

Several days later I posted “There’s More Than One Way To Skin A Cat………….” In summary I delve into EMA approval over FDA and the whole ex-US partnership thing………it may be reading tea leaves or perhaps connecting dots – however one perceives them. The next day I posted about China and its MDS populat...

YMB Censorship and GERON’s ex-US partner? It has been a while since I’ve posted on Imetelchat since most discussions center on the scientific / medical side of Imetelstat – neither of which I have in depth knowledge of, so I’m a bit out of my league here. With that said I have noticed our boards mod...

Great posting Ryan. Earfool is a researching prodigy. I stand in awe at some of the information he has culled from at times the most obscure sources. Keep up the great work Earfool. Your efforts are priceless!!

Thanks Andrew-bp for the well wishes and most of all the amazing forum you host. My wife was the main catalyst behind our move to make a journey of a lifetime. We have a small 22' Tanzer day sailer which we are donating to a Veterans group who take out Vets with disabilities and PTSD and teach them ...

Andrew-bp......Many thanks for the follow up with Jacob and subsequent breakdown of analysis on the inner workings of a drug phase enrollment. I'm still a bit foggy on the numbers and details - but it sounds as if many of those more knowledgeable in this arena are somewhat perplexed as well. When an...

This was posted earlier today on the Yahoo board - many thanks to all of you here for your support and help - especially Chairman of the Imetelchat board - Andrew-bp Greetings fellow longs. What a year it has been. Congratulations to all of you who have held tight and been able to add to your positi...

Currently, there are 57 P3 locations listed on ClinicalTrials.gov - https://clinicaltrials.gov/ct2/show/study/NCT02598661?term=Geron+Corporation&recrs=abd&rank=1&show_locs=Y#locn On June 5, I elicited a response from Jacob Goldberger regarding a request for consideration of a P3 site in Argentina: G...

OPERATION KMALL – That’s A Wrap !!! 6 – Continents: Europe, Africa, Asia, Australia, South America and North America 106 – Countries Europe: (1) England (2) France (3) Germany (4) Italy (5) Spain (6) Iceland (7) Ireland (8) Scotland (9) Norway (10) Sweden (11) Finland (12) Denmark (13) The Netherlan...